Bactericidal activity and resistance development profiling of dalbavancin.
about
Dalbavancin in the treatment of complicated skin and soft-tissue infections: a reviewClinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)Dalbavancin for the treatment of acute bacterial skin and skin structure infectionsNewer antibacterial drugs for a new century.Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax modelExtended-duration dosing and distribution of dalbavancin into bone and articular tissue.Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models.Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unitA comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Treatment of prosthetic osteoarticular infections.Current and prospective treatments for multidrug-resistant gram-positive infections.Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift.Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.Allicin-inspired pyridyl disulfides as antimicrobial agents for multidrug-resistant Staphylococcus aureus.Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
P2860
Q24647429-A83A41E0-DD02-43C5-8C88-2E23E62FDB86Q26746208-34DA4A00-553F-4E65-B8FD-9F6181E895EDQ26799598-261BC5FB-3A83-4038-8369-B0013CA597C8Q30433333-19378043-970C-46B4-8D0A-01E2B5674EA1Q33676316-8F2C63E5-E899-47EE-A0AD-AD0A6B6E7E4FQ35168936-7EB17FF6-91D5-4335-B85F-313CF723BFD4Q36307070-B7D72603-E864-4FD9-A5B0-EC17FFB9FBA2Q36901937-3D6D48A1-877D-4C9A-80D5-0689482D34EEQ37071199-BFA04CBF-C613-45BB-8755-B32FED7EDD50Q37443022-569EC15D-BF7E-4F53-BBEA-0B55001214CCQ37661510-B03372C7-E379-4AEA-8C84-0FA518574870Q37785546-2E15606C-AC04-4237-BF60-A477DCD70E1AQ37853179-AC9EEECC-A64B-4CE1-B1BD-A9B3A32DA947Q38123255-962B5CD1-05CE-46FB-94A5-825A86624473Q38314386-4CCD429C-4765-41CA-BF59-FCFF6A4267D1Q38615330-DBBFDC69-D69C-4CC2-9154-1ED678434478Q38646905-016EC7AE-B38E-48FD-A1BA-6ED5B75FADDCQ39719043-D2C7C691-FE17-4789-95E9-54F18C40D5CEQ40719299-7F9A94AF-B3FD-4420-8CE3-669061F6EA0DQ43066197-2C39B4B7-6CB9-4461-8DAF-4A5313F0D28DQ43405839-F24200B6-1E58-4AB1-A340-6A3B4492CE49Q43834023-52E96698-9CE6-4C22-AC3E-40AFF8D213A6Q45072648-32734CCE-3D22-4146-8984-624194ADD183Q47725737-EF691B56-E520-4626-832E-3E763EBF5AB6
P2860
Bactericidal activity and resistance development profiling of dalbavancin.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Bactericidal activity and resistance development profiling of dalbavancin.
@en
type
label
Bactericidal activity and resistance development profiling of dalbavancin.
@en
prefLabel
Bactericidal activity and resistance development profiling of dalbavancin.
@en
P2093
P2860
P356
P1476
Bactericidal activity and resistance development profiling of dalbavancin.
@en
P2093
Beth P Goldstein
Daniel F Sahm
Daniel J Sheehan
Deborah C Draghi
Patricia Hogan
P2860
P304
P356
10.1128/AAC.00620-06
P407
P577
2007-01-12T00:00:00Z